NEW YORK, Oct. 31 (GenomeWeb News) - Rubicon Genomics will work with Abbott Molecular to develop and sell its MethylPlex tool for detecting prostate and bladder cancers, Rubicon said today.
A methylation detection technology, MethylPlex detects patterns of abnormal DNA methylation in serum and urine during tumor formation and progression. Under the agreement, the tests will combine proprietary Rubicon methylation markers and a simplified method to detect them.
Abbott Molecular is a division of Abbott. Financial details for this agreement were not disclosed.